Retroviridae (e.g., Feline Leukemia Virus, Bovine Leukemia Virus, Avian Leukosis Virus, Equine Infectious Anemia Virus, Rous Sarcoma Virus, Htlv-i, Etc.) Patents (Class 424/207.1)
  • Patent number: 10137192
    Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: November 27, 2018
    Assignee: Sequoia Sciences, Inc.
    Inventors: Gary Eldridge, Steven M Martin
  • Patent number: 9603356
    Abstract: The present invention provides a method that allows the preparation of a cell concentrate in a short time without loss of cells and great damage on cells by simple operations. The present invention provides a method for producing a cell concentrate using an inside-out filtration system for processing a cell suspension, the system including: a cell suspension inlet port; a filtrate outlet port; a cell suspension outlet port; and a hollow fiber separation membrane interposed between the cell suspension inlet port and the cell suspension outlet port, wherein the hollow fiber separation membrane is provided with inner pores with an average pore size of 0.1 ?m to 10 ?m, and the quotient of the division of an initial filtrate flow rate by a linear velocity of the cell suspension flowing through the hollow fibers is 2.5 or less.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: March 28, 2017
    Assignee: KANEKA CORPORATION
    Inventor: Shuhei Taniguchi
  • Patent number: 9555100
    Abstract: Provided herein are, for example, immunogenic compositions and methods of using the same for the treatment or prevention of Herpesvirus infections.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: January 31, 2017
    Assignee: The Regents of the University of California
    Inventors: Deborah H. Spector, Christopher S. Morello, Kimberly A. Kraynyak
  • Patent number: 9476032
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: October 25, 2016
    Assignee: The Research Foundation for The State University of New York
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Patent number: 9462810
    Abstract: The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: October 11, 2016
    Assignee: AJINOMOTO CO., INC.
    Inventors: Hajime Koyama, Tsutomu Arakawa, Daisuke Ejima
  • Patent number: 9023648
    Abstract: The invention is directed to a chimeric gammaretrovirus comprising an gammaretroviral virion which contains a lentiviral Vpx protein and methods of use thereof. In a particular aspect, the chimeric gammaretrovirus is a chimeric murine leukemia virus (MLV) comprising an MLV virion which contains a lentiviral Vpx protein. The invention is also directed to use of the chimeric gammaretrovirus to produce a MLV that can transduce a non-dividing cell (G1/S/G2), transduce a non-dividing cell; enhance the ability of a MLV to transduce a non-dividing cell; transduce a quiescent (G0) cell; and enhance the ability of a human immunodeficiency virus 1 (HIV-1) to transduce a quiescent (G0) cell.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: May 5, 2015
    Assignee: University of Massachusetts
    Inventors: Mario Stevenson, Rajnish Kaushik, Xiaonan Zhu
  • Patent number: 9017935
    Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: April 28, 2015
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie Pacchia
  • Patent number: 8980610
    Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: March 17, 2015
    Assignee: Biogen Idec MA Inc.
    Inventors: Keith Selvitelli, Justin McCue
  • Patent number: 8980280
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: March 17, 2015
    Assignees: Merial, Inc., Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Herve Poulet, Thierry Heidmann
  • Patent number: 8961987
    Abstract: Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related E. coli enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: February 24, 2015
    Assignees: New York University, Molsoft LLC, University of Massachusetts
    Inventors: Susan Zolla-Pazner, Miroslaw K. Gorny, Timothy J. Cardozo, Xiang-peng Kong, Ruben Abagyan, Maxim Totrov, Shan Lu, Abraham Pinter
  • Patent number: 8945583
    Abstract: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: February 3, 2015
    Assignees: Centre National de la Recherche Scientifique, Universite de Montpellier 2
    Inventors: Jean-Luc Georges Laurent Battini, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
  • Publication number: 20150030621
    Abstract: The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.
    Type: Application
    Filed: July 30, 2014
    Publication date: January 29, 2015
    Inventors: Young-Bong KIM, Hee Jung Lee, Nuri Park, Yu-Kyoung Oh
  • Patent number: 8920812
    Abstract: The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: December 30, 2014
    Assignee: Takeda Vaccines, Inc.
    Inventor: Joel R. Haynes
  • Patent number: 8916211
    Abstract: A method and composition for preventing and treating avian influenza utilizes an effective quantity of polyphenolic(s) and its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3?-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3?-gallate, thearubigin, gallic acid, tannic acid, (?)-epigallocatechin gallate (EGCG), (?)epigallocatechin (EGC), (+)-epicatechin (EC), (?)-gallocatechin gallate (GCG), and catechin.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: December 23, 2014
    Assignee: Abattis Bioceuticals Corp.
    Inventors: Charles Hensley, Sung Pyo
  • Publication number: 20140370051
    Abstract: Novel nucleic acids include non-integrative chimeric retroviral genomes including the 5? and 3? long terminal repeat sequences (LTRs) of the caprine lentivirus: the Caprine Arthritis Encephalitis Virus (CAEV) or of another retrovirus not integrating human cells and at least one viral gene of another retrovirus. A vector including such a nucleic acid, an immunogenic or vaccinal composition including the vector or the nucleic acid, as well as their use for treating and/or preventing an infection by a retrovirus or a disease induced by a pathogenic agent are also described.
    Type: Application
    Filed: September 12, 2012
    Publication date: December 18, 2014
    Inventors: Yahia Chebloune, Delphine Aldebert, Géraldine Arrode-Bruses
  • Patent number: 8895027
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: November 25, 2014
    Assignees: Merial Limited, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Hervé Poulet, Thierry Heidmann
  • Publication number: 20140322268
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 30, 2014
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Steven G. REED, Darrick CARTER
  • Patent number: 8846051
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 30, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Publication number: 20140286991
    Abstract: Compositions are provided comprising heat shock protein, immunoglobulins and retroviral antigens to induce systemic and mucosal immunity to infection from retroviruses such as Human Immunodeficiency Virus (HIV). Methods of treatment provided comprise administration of the compositions, which boost the immune systems response to the retroviral antigens or immunogens.
    Type: Application
    Filed: February 23, 2012
    Publication date: September 25, 2014
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Eckhard R. Podack, Natasa Strbo, Genoveffa Franchini, Monica Vaccari
  • Publication number: 20140255445
    Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.
    Type: Application
    Filed: January 24, 2014
    Publication date: September 11, 2014
    Applicant: L'Universite Pierre Et Marie Curie
    Inventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, Francois-Loic Cosset
  • Patent number: 8821856
    Abstract: Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: September 2, 2014
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Pin Wang, Lili Yang
  • Patent number: 8795682
    Abstract: Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: August 5, 2014
    Assignees: Emory University, The UAB Research Foundation, Novavax, Inc.
    Inventors: Richard W. Compans, Baozhong Wang, Beatrice Hahn, Weimin Liu, Gale Smith, Peter Pushko
  • Patent number: 8785411
    Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: July 22, 2014
    Assignee: University of Kansas Medical Center
    Inventor: Zhenqian Liu
  • Patent number: 8716013
    Abstract: Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: May 6, 2014
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Philippe Despres, Pierre Charneau, Frédéric Tangy, Marie-Pascale Frenkiel
  • Patent number: 8709799
    Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: April 29, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Theravectys
    Inventors: Pierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
  • Patent number: 8673612
    Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: March 18, 2014
    Assignee: L'Universite Pierre et Marie Curie
    Inventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, François-Loïc Cosset
  • Publication number: 20140056940
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Application
    Filed: August 29, 2013
    Publication date: February 27, 2014
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, JR., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
  • Patent number: 8652483
    Abstract: The invention relates to a peptide derived from HIV-1 gp120 which forms insoluble aggregates when introduced into an aqueous solution and its use for enhancing viral infection of cells. In addition, the invention comprises methods for enhancing viral infection of cells, for concentrating a virus and for separating a virus from a fluid.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: February 18, 2014
    Inventors: Jan Münch, Frank Kirchhoff, Maral Yolamanova
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Publication number: 20140010839
    Abstract: The present invention relates to an in vitro method of screening for candidate compounds capable of being used for the preventative and/or curative treatment of a disease caused by a retrovirus in which the candidate compound which modulates the expression and/or the activity of the SAMHD1 protein is identified as a candidate compound capable of being used for the preventative and/or curative treatment of a disease caused by a retrovirus. The invention also relates to a vaccine composition and an immunogenic composition, comprising i) an inhibitor of the expression and/or of the activity of the SAMHD1 protein and ii) at least one antigen of a retrovirus.
    Type: Application
    Filed: March 23, 2012
    Publication date: January 9, 2014
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Monsef Benkirane, Nadine Laguette, Bijan Sobhian
  • Publication number: 20130323279
    Abstract: The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide.
    Type: Application
    Filed: May 10, 2013
    Publication date: December 5, 2013
    Applicants: The J. David Gladstone Institutes, Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of California, The Governing Counicl of University of Toronto
    Inventors: Douglas F. Nixon, Keith E. Garrison, Duncan A. Meiklejohn, Mario A. Ostrowski, R. Bradley Jones, Ashish Agrawal, Jack Lenz, Seth Rakoff-Nahoum, Frederick M. Hecht
  • Patent number: 8597657
    Abstract: Mutated viral ENV proteins having mutations in the immunosuppressive domain (ISU) of the transmembrane subunit (TM) have decreased immunosuppressive activity with respect to the wild-type ENV protein. Pharmaceutical compositions that include the protein and nucleic acids coding for the protein are also disclosed.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: December 3, 2013
    Assignees: Institut Gustave Roussy, Centre National de la Recherche Scientifique, Universite Paris Sud XI
    Inventors: Martial Renard, Marianne Mangeney, Thierry Heidmann
  • Patent number: 8541553
    Abstract: The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: September 24, 2013
    Assignee: Baxter Healthcare SA
    Inventors: Johannes Humer, Bernd Mayer, Thomas Muster, Andrea Waltenberger
  • Patent number: 8529909
    Abstract: The subject of the present invention is a method of obtaining purified BLV gp51 antigen as well as a novel ELISA assay using said antigen. The present invention is useful in the diagnosis of enzootic leukaemia in cattle.
    Type: Grant
    Filed: September 27, 2009
    Date of Patent: September 10, 2013
    Assignee: Instytut Immunologii I Terapii
    Inventors: Andrzej Rapak, Ewa Ziolo
  • Publication number: 20130183339
    Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,
    Type: Application
    Filed: March 6, 2013
    Publication date: July 18, 2013
    Applicant: Intercell AG
    Inventor: Intercell AG
  • Patent number: 8460678
    Abstract: The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: June 11, 2013
    Assignees: Institut Pasteur, Institut National de la Santéde la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Véronique Zennou, Hüseyin Firat
  • Patent number: 8449875
    Abstract: The present invention provides targeted lentiviral vectors that are psuedotyped with mutated Sindbis envelopes. For example, mutations in the Sindbis E2 protein are used to alter viral titer, specificity, specificity index, tropism, and susceptibility to host immune response. Typically, one or more of the E1, E2, or E3 proteins can be mutated at one or more amino acid positions. The psuedotyped, targeted lentiviral vectors of the invention are used to transduce heterologous genes into a cell and can be used for in vivo and ex vivo therapeutic applications, as well as for diagnostic and research tool applications.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: May 28, 2013
    Assignee: The Regents of the University of California
    Inventors: Irvin S.Y. Chen, Kouki Morizono
  • Patent number: 8372409
    Abstract: The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: February 12, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Mansour Mohamadzadeh
  • Patent number: 8367068
    Abstract: A method to induce an immune response in a host in need thereof, comprises administering to the host, recombinant lentiviral vector particles comprising: a) a GAG polypeptide or a functional GAG-polypeptide derivative; b) a POL polypeptide or a functional POL-polypeptide derivative ; c) an ENV polypeptide or a functional ENV-polypeptide derivative; and d) a recombinant polynucleotide. The recombinant polynucleotide comprises a transgene placed under the control of regulatory signals for transcription and expression, regulatory signals, of lentiviral origin, for reverse transcription, expression and packaging, and a polynucleotide comprising a cis-acting central initiation region (cPPT) and a cis-acting termination region (CTS). The regions are of lentiviral origin and are inserted in a functional orientation with the regulatory signals of lentiviral origin. The polynucleotide forms a DNA triplex during reverse transcription.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: February 5, 2013
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Véronique Zennou, Hüseyin Firat
  • Patent number: 8349606
    Abstract: The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: January 8, 2013
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Hüseyin Firat, Véronique Zennou
  • Publication number: 20130004538
    Abstract: This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.
    Type: Application
    Filed: July 9, 2012
    Publication date: January 3, 2013
    Inventors: Lee A. Bulla, JR., Jeffrey Marcus Clark, Natalya Griko, Jian Sun, Ralph Clark
  • Publication number: 20120269848
    Abstract: This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample. Methods of generating an immune response against a microorganism are also included.
    Type: Application
    Filed: June 18, 2012
    Publication date: October 25, 2012
    Inventors: George A. Scheele, James E. Hildreth
  • Patent number: 8287881
    Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: October 16, 2012
    Assignee: GENEART AG
    Inventors: Ralf Wagner, Markus Graf, Ludwig Deml, Kurt Bieler
  • Publication number: 20120251537
    Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 4, 2012
    Inventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe
  • Patent number: 8263085
    Abstract: The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.
    Type: Grant
    Filed: September 24, 2007
    Date of Patent: September 11, 2012
    Assignees: The Cleveland Clinic Foundation, The Regents of the University of California
    Inventors: Robert H. Silverman, Eric A. Klein, Graham Casey, Joseph DeRisi, Don Ganem
  • Publication number: 20120213817
    Abstract: The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide.
    Type: Application
    Filed: November 3, 2010
    Publication date: August 23, 2012
    Inventor: Joel R. Haynes
  • Patent number: 8236558
    Abstract: BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: August 7, 2012
    Assignee: Novartis AG
    Inventors: Tianci Luo, Robert Berkowitz, Michael Kaleko
  • Publication number: 20120189572
    Abstract: The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host.
    Type: Application
    Filed: November 6, 2009
    Publication date: July 26, 2012
    Inventors: Wei-Zen Wei, Gen Sheng Wu, Marie P. Piechocki, Richard F. Jones
  • Publication number: 20120177670
    Abstract: A method of treating a cellular proliferative disorder with cancer antigen-activated dendritic cells that are derived from a population of somatic stem cells. Also disclosed are methods of treating tissue damages and degenerative diseases with a population of somatic stem cells.
    Type: Application
    Filed: February 6, 2012
    Publication date: July 12, 2012
    Applicant: StemBios Technologies, Inc.
    Inventor: James Wang
  • Patent number: 8182820
    Abstract: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: May 22, 2012
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Janet K. Yamamoto, Jennifer White Janelle, Barbara Aurea Torres, Maki Arai, Taishi Tanabe, Ruiyu Pu